Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lifileucel - Iovance Biotherapeutics

Next Previous
X
Search
Drug Profile

Lifileucel - Iovance Biotherapeutics

Alternative Names: AMTAGVI; Autologous TILs - Iovance Biotherapeutics; Contego™ - Iovance Biotherapeutics; LN-144; Tumour infiltrating lymphocytes - Iovance Biotherapeutics

Latest Information Update: 16 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genesis Biopharma
  • Developer Iovance Biotherapeutics
  • Class Antineoplastics; Cell therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Registered Malignant melanoma
  • Phase II Endometrial cancer
  • Phase I Solid tumours; Uveal melanoma

Most Recent Events

  • 08 Aug 2024 Iovance Biotherapeutics announces intention for Regulatory submission for Malignant melanoma in Switzerland and other countries in the second half of 2025 and early 2026
  • 01 Jul 2024 Iovance Biotherapeutics plans a phase II trial for Endometrial cancer (Second-line therapy or greater, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in October 2024 (IV) (NCT06481592)
  • 30 Jun 2024 Phase-II clinical trials in Endometrial cancer (Second-line therapy or greater, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) (IV) (NCT06481592)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top